EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma

Luciano J Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M A Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Chai Hyun Kim, Paul Cislo, David M Hughes, Guido Nador und 1 weitere

Blood and Lymphatic Cancer: Targets and Therapy · 2025-06 · Volume 15 · 11-20

DOI: 10.2147/blctt.s516356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2025-06. Verfasst von Luciano J Costa und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, Birmingham, AL, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

bispecific antibodyclinical trialefficacyelectronic health recordhematology

Autor:innen und Institutionen

  • University of Alabama at Birmingham, Birmingham, AL, USA.
  • Duke University School of Medicine, Durham, NC, USA.
  • Bethanien Hospital, Frankfurt, Germany.
  • Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • STATLOG Inc, Montreal, QC, Canada.
  • Chief Medical Affairs Office, Pfizer Inc, New York, NY, USA.

ORCID-Profile: Marco DiBonaventura

Zitieren

APA

Costa, L. J., LeBlanc, T. W., Tesch, H., Sonneveld, P., Johnson, S. M. A., Vekeman, F., Hlavacek, P., Meche, A., Kim, C. H., Cislo, P., Hughes, D. M., Nador, G., & DiBonaventura, M. (2025). An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma. Blood and Lymphatic Cancer: Targets and Therapy, Volume 15, 11-20. https://doi.org/10.2147/blctt.s516356

Vancouver

Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SMA, Vekeman F, et al. An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma. Blood and Lymphatic Cancer: Targets and Therapy. 2025;Volume 15:11-20. doi:10.2147/blctt.s516356

BibTeX
@article{Costa2025,
  author = {Costa, Luciano J and LeBlanc, Thomas W and Tesch, Hans and Sonneveld, Pieter and Johnson, Sarasa M A and Vekeman, Francis and Hlavacek, Patrick and Meche, Aster and Kim, Chai Hyun and Cislo, Paul and Hughes, David M and Nador, Guido and DiBonaventura, Marco},
  title = {An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma},
  journal = {Blood and Lymphatic Cancer: Targets and Therapy},
  year = {2025},
  volume = {Volume 15},
  pages = {11--20},
  doi = {10.2147/blctt.s516356}
}
Kostenlos starten →